---
figid: PMC6319910__nihms-993243-f0002
figtitle: RAS–RAF–MEK–ERK pathway is activated in many types of cancer
organisms:
- Homo sapiens
- Mus musculus
- unidentified
organisms_ner:
- Mus musculus
- Drosophila melanogaster
pmcid: PMC6319910
filename: nihms-993243-f0002.jpg
figlink: /pmc/articles/PMC6319910/figure/F2/
number: F2
caption: RAS–RAF–MEK–ERK pathway is activated in many types of cancer. Trametinib
  inhibits MEK1/2, blocking the activation of ERK1/2. Dabrafenib and vemurafenib inhibit
  RAF activation.Trametinib and dabrafenib are used in combination to treat BRAF V600
  mutated melanoma
papertitle: 'Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report,
  Literature Review, and Consideration of Mechanism.'
reftext: Mary Banks, et al. Cardiovasc Toxicol. 2017 Oct;17(4):487-493.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9667277
figid_alias: PMC6319910__F2
figtype: Figure
redirect_from: /figures/PMC6319910__F2
ndex: cde2aa72-decc-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6319910__nihms-993243-f0002.html
  '@type': Dataset
  description: RAS–RAF–MEK–ERK pathway is activated in many types of cancer. Trametinib
    inhibits MEK1/2, blocking the activation of ERK1/2. Dabrafenib and vemurafenib
    inhibit RAF activation.Trametinib and dabrafenib are used in combination to treat
    BRAF V600 mutated melanoma
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Braf
  - Braf-rs1
  - Mdk
  - Map2k1
  - Map2k2
  - Ephb2
  - Mapk1
  - Mapk3
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - trametinib
  - dabrafenib
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
